Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762370 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
A Phase 2 study of Type 2 Diabetes Mellitus and Osteoarthritis of the Knee, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 8
- Study locations
NCT02762370: Completed Phase 2 study of Type 2 Diabetes Mellitus and Osteoarthritis of the Knee, sponsored by Pacira Pharmaceuticals.
NCT02762370 is a Phase 2 study of Type 2 Diabetes Mellitus and Osteoarthritis of the Knee that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 33 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02762370, a Phase 2 study of Type 2 Diabetes Mellitus and Osteoarthritis of the Knee, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with osteoarthritis (OA) of the knee and Type 2 diabetes mellitus (DM).
Primary Outcome
Average blood glucose was analyzed with a mixed model for repeated measures (MMRM)
Conditions Studied
Interventions
- DRUG FX006 32 mg
- DRUG TCA IR 40 mg
Study Locations (8)
California
- - Anaheim
- - El Cajon
- - North Hollywood
Texas
- - Dallas
- - San Antonio
Pennsylvania
- - Duncansville
South Carolina
- - Mt. Pleasant
Tennessee
- - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT02762370 record still lists
NCT02762370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which FX006 32 mg is the first listed.
NCT02762370 lists 8 locations in 5 states (California, Texas, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02762370 about?
NCT02762370 is a clinical study titled "Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes". The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with osteoarthritis (OA) of the knee and Type 2 diabetes mellitus (DM).
What is the current status of trial NCT02762370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-04. Estimated completion is 2016-11.
What conditions does trial NCT02762370 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Osteoarthritis of the Knee.
What interventions are being tested in trial NCT02762370?
The interventions under investigation include: FX006 32 mg (DRUG), TCA IR 40 mg (DRUG).
Who is sponsoring clinical trial NCT02762370?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02762370 being conducted?
This trial has 8 study locations across California, Pennsylvania, South Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02762370's enrollment target sits among peer trials
33 90th of 130 higher than 41 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia